Phylogenetic identification of bacterial MazF toxin protein motifs among probiotic strains and foodborne pathogens and potential implications of engineered probiotic intervention in food

Cell and Bioscience

Volumn 2, Issue 1, 2012, Pages

  Yan, Xianghe ^a   Gurtler, Joshua B ^a   Fratamico, Pina M ^a   Hu, Jing ^b   Juneja, Vijay K ^a  

^a EASTERN REGIONAL RESEARCH CENTER   (United States)

^b FRANKLIN AND MARSHALL COLLEGE   (United States)

Author keywords

engineered probiotics; foodborne pathogens; probiotic cocktail; toxin antitoxin module

Indexed keywords

ARCHAEA; BACTERIA (MICROORGANISMS);

EID: 84870933954     PISSN: None     EISSN: 20453701     Source Type: Journal    
DOI: 10.1186/2045-3701-2-39     Document Type: Article

References (77)

1. World Health Organization (WHO), Food and Agriculture Organization of the United Nations, and the World Organization for Animal Health Expert workshop on non-human antimicrobial usage and antimicrobial resistance 2003, Geneva, http://www.who.int/foodsafety/publications/micro/en/amr.pdf, World Health Organization (WHO), Food and Agriculture Organization of the United Nations, and the World Organization for Animal Health.
2. CDC Are antibacterial-containing products (soaps, household cleaners, etc.) better for preventing the spread of infection? Does their use add to the problem of resistance? 2009, Antibiotic Resistance Questions & Answers, Centers for Disease Control and Prevention, Atlanta, CDC.
3. Ferber D. Antibiotic resistance. Livestock feed ban preserves drugs' power. Science 2002, 295:27-28.
4. Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005, 365:579-587.
5. Mathew AG, Cissell R, Liamthong S. Antibiotic resistance in bacteria associated with food animals: a United States perspective of livestock production. Foodborne Pathog Dis 2007, 4:115-133. 10.1089/fpd.2006.0066, 17600481.
6. WHO Use of antimicrobials outside human medicine and resultant antimicrobial resistance in humans [R] 2002, World Health Organization, http://www.who.int/mediacentre/factsheets/fs268/en/index.html, WHO.
7. Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 2005, 102:11070-11075. 10.1073/pnas.0504978102, 1176910, 16033867.
8. Possemiers S, Grootaert C, Vermeiren J, Gross G, Marzorati M, Verstraete W, Van de Wiele T. The intestinal environment in health and disease - recent insights on the potential of intestinal bacteria to influence human health. Curr Pharm Des 2009, 15:2051-2065. 10.2174/138161209788489159, 19519443.
9. De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S, Collini S, Pieraccini G, Lionetti P. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci U S A 2010, 107:14691-14696. 10.1073/pnas.1005963107, 2930426, 20679230.
10. Qu A, Brulc JM, Wilson MK, Law BF, Theoret JR, Joens LA, Konkel ME, Angly F, Dinsdale EA, Edwards RA, Nelson KE, White BA. Comparative metagenomics reveals host specific metavirulomes and horizontal gene transfer elements in the chicken cecum microbiome. PLoS One 2008, 3:e2945. 10.1371/journal.pone.0002945, 2492807, 18698407.
11. Torok VA, Ophel-Keller K, Loo M, Hughes RJ. Application of methods for identifying broiler chicken gut bacterial species linked with increased energy metabolism. Appl Environ Microbiol 2008, 74:783-791. 10.1128/AEM.01384-07, 2227708, 18065621.
12. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, Sogin ML, Jones WJ, Roe BA, Affourtit JP, Egholm M, Henrissat B, Heath AC, Knight R, Gordon JI. A core gut microbiome in obese and lean twins. Nature 2009, 457:480-484. 10.1038/nature07540, 2677729, 19043404.
13. Tap J, Mondot S, Levenez F, Pelletier E, Caron C, Furet JP, Ugarte E, Munoz-Tamayo R, Paslier DL, Nalin R, Dore J, Leclerc M. Towards the human intestinal microbiota phylogenetic core. Environ Microbiol 2009, 11:2574-2584. 10.1111/j.1462-2920.2009.01982.x, 19601958.
14. Cabana MD, Shane AL, Chao C, Oliva-Hemker M. Probiotics in primary care pediatrics. Clin Pediatr (Phila) 2006, 45:405-410.
15. Cadieux P, Wind A, Sommer P, Schaefer L, Crowley K, Britton RA, Reid G. Evaluation of reuterin production in urogenital probiotic Lactobacillus reuteri RC-14. Appl Environ Microbiol 2008, 74:4645-4649. 10.1128/AEM.00139-08, 2519358, 18539802.
16. Cadieux PA, Burton J, Devillard E, Reid G. Lactobacillus by-products inhibit the growth and virulence of uropathogenic Escherichia coli. J Physiol Pharmacol 2009, 60(Suppl 6):13-18.
17. Canny GO, McCormick BA. Bacteria in the intestine, helpful residents or enemies from within?. Infect Immun 2008, 76:3360-3373. 10.1128/IAI.00187-08, 2493210, 18474643.
18. Gillor O, Etzion A, Riley MA. The dual role of bacteriocins as anti- and probiotics. Appl Microbiol Biotechnol 2008, 81:591-606. 10.1007/s00253-008-1726-5, 2670069, 18853155.
19. Lidbeck A, Edlund C, Gustafsson JA, Kager L, Nord CE. Impact of Lactobacillus acidophilus on the normal intestinal microflora after administration of two antimicrobial agents. Infection 1988, 16:329-336. 10.1007/BF01644541, 3146551.
20. Ng SC, Hart AL, Kamm MA, Stagg AJ, Knight SC. Mechanisms of action of probiotics: recent advances. Inflamm Bowel Dis 2009, 15:300-310. 10.1002/ibd.20602, 18626975.
21. Reid G, Bruce AW. Urogenital infections in women: can probiotics help?. Postgrad Med J 2003, 79:428-432. 10.1136/pmj.79.934.428, 1742800, 12954951.
22. Reid G, Jass J, Sebulsky MT, McCormick JK. Potential uses of probiotics in clinical practice. Clin Microbiol Rev 2003, 16:658-672. 10.1128/CMR.16.4.658-672.2003, 207122, 14557292.
23. Reid G, Sanders ME, Gaskins HR, Gibson GR, Mercenier A, Rastall R, Roberfroid M, Rowland I, Cherbut C, Klaenhammer TR. New scientific paradigms for probiotics and prebiotics. J Clin Gastroenterol 2003, 37:105-118. 10.1097/00004836-200308000-00004, 12869879.
24. Grady R, Hayes F. Axe-Txe, a broad-spectrum proteic toxin-antitoxin system specified by a multidrug-resistant, clinical isolate of Enterococcus faecium. Mol Microbiol 2003, 47:1419-1432. 10.1046/j.1365-2958.2003.03387.x, 12603745.
25. Masuda Y, Miyakawa K, Nishimura Y, Ohtsubo E. chpA and chpB, Escherichia coli chromosomal homologs of the pem locus responsible for stable maintenance of plasmid R100. J Bacteriol 1993, 175:6850-6856. 206809, 8226627.
26. Masuda Y, Ohtsubo E. Mapping and disruption of the chpB locus in Escherichia coli. J Bacteriol 1994, 176:5861-5863. 196794, 8083180.
27. Gerdes K, Christensen SK, Lobner-Olesen A. Prokaryotic toxin-antitoxin stress response loci. Nat Rev Microbiol 2005, 3:371-382. 10.1038/nrmicro1147, 15864262.
28. Kolodkin-Gal I, Verdiger R, Shlosberg-Fedida A, Engelberg-Kulka H. A differential effect of E. coli toxin-antitoxin systems on cell death in liquid media and biofilm formation. PLoS One 2009, 4:e6785. 10.1371/journal.pone.0006785, 2727947, 19707553.
29. Mittenhuber G. Occurrence of mazEF-like antitoxin/toxin systems in bacteria. J Mol Microbiol Biotechnol 1999, 1:295-302.
30. Sat B, Hazan R, Fisher T, Khaner H, Glaser G, Engelberg-Kulka H. Programmed cell death in Escherichia coli: some antibiotics can trigger mazEF lethality. J Bacteriol 2001, 183:2041-2045. 10.1128/JB.183.6.2041-2045.2001, 95100, 11222603.
31. Johnson EP, Strom AR, Helinski DR. Plasmid RK2 toxin protein ParE: purification and interaction with the ParD antitoxin protein. J Bacteriol 1996, 178:1420-1429. 177817, 8631720.
32. Santos-Sierra S, Pardo-Abarrio C, Giraldo R, Diaz-Orejas R. Genetic identification of two functional regions in the antitoxin of the parD killer system of plasmid R1. FEMS Microbiol Lett 2002, 206:115-119. 10.1111/j.1574-6968.2002.tb10995.x, 11786266.
33. Sobecky PA, Easter CL, Bear PD, Helinski DR. Characterization of the stable maintenance properties of the par region of broad-host-range plasmid RK2. J Bacteriol 1996, 178:2086-2093. 177909, 8606188.
34. Zhang Y, Zhu L, Zhang J, Inouye M. Characterization of ChpBK, an mRNA interferase from Escherichia coli. J Biol Chem 2005, 280:26080-26088. 10.1074/jbc.M502050200, 15901733.
35. Bech FW, Jorgensen ST, Diderichsen B, Karlstrom OH. Sequence of the relB transcription unit from Escherichia coli and identification of the relB gene. EMBO J 1985, 4:1059-1066. 554300, 2990907.
36. Gotfredsen M, Gerdes K. The Escherichia coli relBE genes belong to a new toxin-antitoxin gene family. Mol Microbiol 1998, 29:1065-1076. 10.1046/j.1365-2958.1998.00993.x, 9767574.
37. Gunn JS, Miller SI. PhoP-PhoQ activates transcription of pmrAB, encoding a two-component regulatory system involved in Salmonella typhimurium antimicrobial peptide resistance. J Bacteriol 1996, 178:6857-6864. 178586, 8955307.
38. Lippa AM, Goulian M. Feedback inhibition in the PhoQ/PhoP signaling system by a membrane peptide. PLoS Genet 2009, 5:e1000788. 10.1371/journal.pgen.1000788, 2789325, 20041203.
39. Monsieurs P, De Keersmaecker S, Navarre WW, Bader MW, De Smet F, McClelland M, Fang FC, De Moor B, Vanderleyden J, Marchal K. Comparison of the PhoPQ regulon in Escherichia coli and Salmonella typhimurium. J Mol Evol 2005, 60:462-474. 10.1007/s00239-004-0212-7, 15883881.
40. Zwir I, Shin D, Kato A, Nishino K, Latifi T, Solomon F, Hare JM, Huang H, Groisman EA. Dissecting the PhoP regulatory network of Escherichia coli and Salmonella enterica. Proc Natl Acad Sci U S A 2005, 102:2862-2867. 10.1073/pnas.0408238102, 548500, 15703297.
41. Amitai S, Kolodkin-Gal I, Hananya-Meltabashi M, Sacher A, Engelberg-Kulka H. Escherichia coli MazF leads to the simultaneous selective synthesis of both " death proteins" and " survival proteins" . PLoS Genet 2009, 5(3):e1000390. 10.1371/journal.pgen.1000390, 2646832, 19282968.
42. Amitai S, Yassin Y, Engelberg-Kulka H. MazF-mediated cell death in Escherichia coli: a point of no return. J Bacteriol 2004, 186:8295-8300. 10.1128/JB.186.24.8295-8300.2004, 532418, 15576778.
43. Park JH, Yamaguchi Y, Inouye M. Intramolecular regulation of the sequence-specific mRNA interferase activity of MazF fused to a MazE fragment with a linker cleavable by specific proteases. Appl Environ Microbiol 2012, 78(11):3794-3799. 10.1128/AEM.00364-12, 3346410, 22447587.
44. Belitsky M, Avshalom H, Erental A, Yelin I, Kumar S, London N, Sperber M, Schueler-Furman O, Engelberg-Kulka H. The Escherichia coli extracellular death factor EDF induces the endoribonucleolytic activities of the toxins MazF and ChpBK. Mol Cell 2012, 41(6):625-635.
45. Engelberg-Kulka H, Sat B, Reches M, Amitai S, Hazan R. Bacterial programmed cell death systems as targets for antibiotics. Trends Microbiol 2004, 12(2):66-71. 10.1016/j.tim.2003.12.008, 15036322.
46. Rothenbacher FP, Suzuki M, Hurley JM, Montville TJ, Kirn TJ, Ouyang M, Woychik NA. Clostridium difficile MazF toxin exhibits selective, not global, mRNA cleavage. J Bacteriol 2012, 194(13):3464-3474. 10.1128/JB.00217-12, 22544268.
47. Juneja VK, Dwivedi HP, Yan X. Novel natural food antimicrobials. Annu Rev Food Sci Technol 2012, 3:381-403. 10.1146/annurev-food-022811-101241, 22385168.
48. de Vuyst L, Vandamme E. Antimicrobial potential of lactic acid bacteria. Bacteriocins of Lactic Acid Bacteria. Microbiology, Genetics and Applications 1994, 91-142. Blackie Acad Prof, London, Vuyst L, Vandamme EJ.
49. Shornikova AV, Casas IA, Isolauri E, Mykkanen H, Vesikari T. Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children. J Pediatr Gastroenterol Nutr 1997, 24:399-404. 10.1097/00005176-199704000-00008, 9144122.
50. Williams MD, Ha CY, Ciorba MA. Probiotics as therapy in gastroenterology: a study of physician opinions and recommendations. J Clin Gastroenterol 2010, 44:631-636.
51. Goldin BR, Gorbach SL, Saxelin M, Barakat S, Gualtieri L, Salminen S. Survival of Lactobacillus species (strain GG) in human gastrointestinal tract. Dig Dis Sci 1992, 37:121-128. 10.1007/BF01308354, 1728516.
52. Plummer S, Weaver MA, Harris JC, Dee P, Hunter J. Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. Int Microbiol 2004, 7:59-62.
53. Vanderhoof JA, Whitney DB, Antonson DL, Hanner TL, Lupo JV, Young RJ. Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children. J Pediatr 1999, 135:564-568. 10.1016/S0022-3476(99)70053-3, 10547243.
54. Vanderhoof JA, Young RJ. Current and potential uses of probiotics. Ann Allergy Asthma Immunol 2004, 93:S33-S37. 10.1016/S1081-1206(10)61730-9, 15562872.
55. Arber W. Genetic variation: molecular mechanisms and impact on microbial evolution. FEMS Microbiol Rev 2000, 24:1-7. 10.1111/j.1574-6976.2000.tb00529.x, 10640595.
56. Saito H, Kashida S, Inoue T, Shiba K. The role of peptide motifs in the evolution of a protein network. Nucleic Acids Res 2007, 35:6357-6366. 10.1093/nar/gkm692, 2095796, 17881369.
57. Hadorn B, Steiner N, Sumida C, Peters TJ. Intestinal enterokinase. Mechanisms of tts " secretion" into the lumen of the small intestine. Lancet 1971, 1:165-166.
58. Kitamoto Y, Yuan X, Wu Q, McCourt DW, Sadler JE. Enterokinase, the initiator of intestinal digestion, is a mosaic protease composed of a distinctive assortment of domains. Proc Natl Acad Sci U S A 1994, 91:7588-7592. 10.1073/pnas.91.16.7588, 44447, 8052624.
59. Song HW, Choi SI, Seong BL. Engineered recombinant enteropeptidase catalytic subunit: effect of N-terminal modification. Arch Biochem Biophys 2002, 400:1-6. 10.1006/abbi.2001.2737, 11913964.
60. Zhang Y, Vankemmelbeke MN, Holland LE, Walker DC, James R, Penfold CN. Investigating early events in receptor binding and translocation of colicin E9 using synchronized cell killing and proteolytic cleavage. J Bacteriol 2008, 190:4342-4350. 10.1128/JB.00047-08, 2446772, 18408035.
61. Hildebrand F, Meyer A, Eyre-Walker A. Evidence of Selection upon Genomic GC-Content in Bacteria. PLoS Genet 2010, 6(9):e1001107. 10.1371/journal.pgen.1001107, 2936529, 20838593.
62. Bentley SD, Parkhill J. Comparative genomic structure of prokaryotes. Annu Rev Genet 2004, 38:771-792. 10.1146/annurev.genet.38.072902.094318, 15568993.
63. Touchon M, Hoede C, Tenaillon O, Barbe V, Baeriswyl S, Bidet P, Bingen E, Bonacorsi S, Bouchier C, Bouvet O, Calteau A, Chiapello H, Clermont O, Cruveiller S, Danchin A, Diard M, Dossat C, Karoui ME, Frapy E, Garry L, Ghigo JM, Gilles AM, Johnson J, Le Bouguenec C, Lescat M, Mangenot S, Martinez-Jehanne V, Matic I, Nassif X, Oztas S, et al. Organised genome dynamics in the Escherichia coli species results in highly diverse adaptive paths. PLoS Genet 2009, 5:e1000344. 10.1371/journal.pgen.1000344, 2617782, 19165319.
64. Canani RB, Cirillo P, Terrin G, Cesarano L, Spagnuolo MI, De Vincenzo A, Albano F, Passariello A, De Marco G, Manguso F, Guarino A. Probiotics for treatment of acute diarrhoea in children: randomised clinical trial of five different preparations. BMJ 2007, 335:340. 10.1136/bmj.39272.581736.55, 1949444, 17690340.
65. Weizman Z, Asli G, Alsheikh A. Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents. Pediatrics 2005, 115:5-9.
66. Quigley EMM, Sanders ME. Probiotic foods for gastrointestinal health. Gastroenterology & Endoscopy News Special Edition 2009, 7:27-33. 3508526, 23213581.
67. Corr SC, Gahan CG, Hill C. Impact of selected Lactobacillus and Bifidobacterium species on Listeria monocytogenes infection and the mucosal immune response. FEMS Immunol Med Microbiol 2007, 50:380-388. 10.1111/j.1574-695X.2007.00264.x, 17537177.
68. Marteau P, Seksik P. Tolerance of probiotics and prebiotics. J Clin Gastroenterol 2004, 38:S67-S69. 10.1097/01.mcg.0000128929.37156.a7, 15220662.
69. Marteau P, Seksik P, Lepage P, Dore J. Cellular and physiological effects of probiotics and prebiotics. Mini Rev Med Chem 2004, 4:889-896. 10.2174/1389557043403369, 15544550.
70. Mack DR, Michail S, Wei S, McDougall L, Hollingsworth MA. Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol 1999, 276:G941-G950.
71. Klaenhammer TR, Kullen MJ. Selection and design of probiotics. Int J Food Microbiol 1999, 50:45-57. 10.1016/S0168-1605(99)00076-8, 10488843.
72. Cursino L, Smajs D, Smarda J, Nardi RM, Nicoli JR, Chartone-Souza E, Nascimento AM. Exoproducts of the Escherichia coli strain H22 inhibiting some enteric pathogens both in vitro and in vivo. J Appl Microbiol 2006, 100:821-829. 10.1111/j.1365-2672.2006.02834.x, 16553738.
73. Iacono A, Raso GM, Canani RB, Calignano A, Meli R. Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. J Nutr Biochem 2010, 22:699-711.
74. Lu TK, Collins JJ. Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proc Natl Acad Sci U S A 2009, 106:4629-4634. 10.1073/pnas.0800442106, 2649960, 19255432.
75. Westwater C, Kasman LM, Schofield DA, Werner PA, Dolan JW, Schmidt MG, Norris JS. Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections. Antimicrob Agents Chemother 2003, 47:1301-1307. 10.1128/AAC.47.4.1301-1307.2003, 152521, 12654662.
76. Drummond A, Ashton B, Buxton S. Geneious v5.4 2011, http://www.geneious.com.
77. Kearse M, Moir R, Wilson A, Stones-Havas S, Cheung M, Sturrock S, Buxton S, Cooper A, Markowitz S, Duran C, et al. Geneious Basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data. Bioinformatics 2012, 28(12):1647-1649. 10.1093/bioinformatics/bts199, 3371832, 22543367.